InflammaDry®
InflammaDry is the first and only rapid, point-of-care test to detect for MMP-9, an inflammatory marker that has consistently been shown to be elevated in the tears of patients with Dry Eye disease.[1]
This in-office test is easy to administer allowing for the rapid detection of MMP-9 directly from human eye fluid on the inside of the lower eyelid (palpebral conjunctiva). InflammaDry kits are individually packaged and do not require any additional equipment to administer or interpret. Results are achieved in 10 minutes allowing you to provide a diagnosis and implement an appropriate treatment plan before your patient leaves the office.
Click to hear what leading industry experts have to say about InflammaDry
Right Diagnosis
- Increased MMP-9 activity in dry eyes may contribute to deranged corneal epithelial barrier function, increased corneal desquamation and corneal surface irregularity [2]
- Studies show that diagnosis and treatment of Dry Eye disease prior to LASIK surgery may result in improved wound healing and reduced complications [3-4]
- Sensitivity: 87% [5]
- Specificity: 92% [5]
Right Treatment
- Signs and symptoms noticeably improve with anti-inflammatory therapies such as corticosteroids and cyclosporine [6-7]
- Dry Eye disease may require an extensive treatment plan including continuous therapy
Right Now
- Results in 10 minutes
Click here to download additional information about InflammaDry
[1] Chotikavanich S, de Paiva CS, Li de Quan, Chen JJ, Bian F, Farley WJ, Pflugfelder SC. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3203-9.
[2] de Paiva S, Lindsey JL, Pflugfelder SC. Assessing the severity of keratitis sicca with videokeratoscopic indices. Ophthalmology 2003; 110:1102–1109.
[3] Fournié PR, Gordon GM, Dawson DG, Malecaze FJ, Edelhauser H, Fini ME. Correlation Between Epithelial Ingrowth and Basement Membrane Remodeling in Human Corneas After Laser-Assisted In Situ Keratomileusis. Arch Ophthalmol. 2010; 128(4):426-436.
[4] Tetsuya Mutoh, Masaya Nishio, Yukihiro Matsumoto, and Kiyomi Arai. Correlation between the matrix metalloproteinase-9 activity and chondroitin sulfate concentrations in tear fluid after laser in situ keratomileusis. Clin Ophthalmol. 2010; 4: 823–828.
[5] The RPS InflammaDry Detector's sensitivity and specificity was compared to clinical truth in RPS clinical study: protocol number 09-001, version number 2.4.
[6] Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. Ophthalmology 1999; 106:811–816.
[7] Sall K, Stevenson OD, Mundorf TK, Reis BL, CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631–9.
[1] Chotikavanich S, de Paiva CS, Li de Quan, Chen JJ, Bian F, Farley WJ, Pflugfelder SC. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3203-9.
[2] de Paiva S, Lindsey JL, Pflugfelder SC. Assessing the severity of keratitis sicca with videokeratoscopic indices. Ophthalmology 2003; 110:1102–1109.
[3] Fournié PR, Gordon GM, Dawson DG, Malecaze FJ, Edelhauser H, Fini ME. Correlation Between Epithelial Ingrowth and Basement Membrane Remodeling in Human Corneas After Laser-Assisted In Situ Keratomileusis. Arch Ophthalmol. 2010; 128(4):426-436.
[4] Tetsuya Mutoh, Masaya Nishio, Yukihiro Matsumoto, and Kiyomi Arai. Correlation between the matrix metalloproteinase-9 activity and chondroitin sulfate concentrations in tear fluid after laser in situ keratomileusis. Clin Ophthalmol. 2010; 4: 823–828.
[5] The RPS InflammaDry Detector's sensitivity and specificity was compared to clinical truth in RPS clinical study: protocol number 09-001, version number 2.4.
[6] Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. Ophthalmology 1999; 106:811–816.
[7] Sall K, Stevenson OD, Mundorf TK, Reis BL, CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631–9.